{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:20:17Z","timestamp":1783441217140,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jnma.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:17:04Z","timestamp":1540945024000},"page":"262-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data"],"prefix":"10.1016","volume":"111","author":[{"given":"D\u00f6nd\u00fc","family":"\u00dcsk\u00fcdar Cansu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hava","family":"\u00dcsk\u00fcdar Teke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncer","family":"Temel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jnma.2018.10.003_bib1","series-title":"Primer on the Rheumatic Diseases","first-page":"193","article-title":"Ankylosing spondylitis","author":"Van der Heijde","year":"2008"},{"key":"10.1016\/j.jnma.2018.10.003_bib2","first-page":"696","article-title":"Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis","volume":"18","author":"Edmunds","year":"1991","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jnma.2018.10.003_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/1744666X.2014.866038","article-title":"Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases","volume":"10","author":"Wendling","year":"2014","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.jnma.2018.10.003_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12891-015-0489-2","article-title":"Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis","volume":"16","author":"Wu","year":"2015","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.jnma.2018.10.003_bib6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jnma.2018.10.003_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.jnma.2018.10.003_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jnma.2018.10.003_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.crohns.2013.06.001","article-title":"European consensus on the histopathology of inflammatory bowel disease","volume":"7","author":"Magro","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jnma.2018.10.003_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000239","article-title":"Subclinical gut inflammation in ankylosing spondylitis","volume":"28","author":"Ciccia","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"Rudwaleit","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib12","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jnma.2018.10.003_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5946\/ce.2012.45.2.138","article-title":"Non-steroidal anti-inflammatory drug-induced enteropathy","volume":"45","author":"Lim","year":"2012","journal-title":"Clin Endoscopy"},{"key":"10.1016\/j.jnma.2018.10.003_bib14","first-page":"214","article-title":"Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS","volume":"34","author":"Essers","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib15","first-page":"22","article-title":"Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: a study in the AQUILES cohort","volume":"12","author":"Garcia-Vicuna","year":"2016","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jnma.2018.10.003_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0889-857X(05)70042-9","article-title":"Bowel inflammation and the spondyloarthropathies","volume":"24","author":"De Keyser","year":"1998","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.jnma.2018.10.003_bib17","first-page":"2279","article-title":"The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint","volume":"22","author":"Mielants","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/03009749009097071","article-title":"Follow-up study of ankylosing spondylitis over a period of 12 years (1977\u20131989)","volume":"87","author":"Dekker-Saeys","year":"1990","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.jnma.2018.10.003_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jnma.2018.10.003_bib20","first-page":"1105","article-title":"Inflammatory bowel disease: historical perspective, epidemiology, and risk factors","volume":"95","author":"Malik","year":"2015","journal-title":"Surg Clin"},{"key":"10.1016\/j.jnma.2018.10.003_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.1780270301","article-title":"The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jnma.2018.10.003_bib22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","article-title":"Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept","volume":"38","author":"van Dijken","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib23","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2013.834961","article-title":"Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis","volume":"43","author":"van der Heijde","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jnma.2018.10.003_bib25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O'Toole","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jnma.2018.10.003_bib26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jnma.2018.10.003_bib27","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jnma.2018.10.003_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","article-title":"Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors","volume":"60","author":"Berg","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jnma.2018.10.003_bib29","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002796841730158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002796841730158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T13:37:40Z","timestamp":1706017060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002796841730158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S002796841730158X"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2018.10.003","relation":{},"ISSN":["0027-9684"],"issn-type":[{"value":"0027-9684","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Medical Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}